Proteomics

Dataset Information

0

USP25 is a HIF-1 regulator and a therapeutic target in pancreatic ductal adenocarcinoma


ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with both an extremely poor prognosis and response to conventional chemotherapy. Identifying novel biological vulnerabilities is therefore critical in the development of more effective therapies. By using patient-derived organoids and murine genetic models, we developed a pipeline for identifying biologically active deubiquitylases (DUBs) with activity-based proteomics, coupled with a loss-of-function genetic screen in organoids. We found that ubiquitin specific protease 25 (USP25) is indispensable for PDAC progression. Compared with normal pancreatic tissue, USP25 was highly expressed and active in murine PDAC tumours and in primary human PDAC samples. Silencing of Usp25/USP25 led to reduced tumour organoid formation and viability, and transcriptional profiling revealed that USP25 is a regulator of hypoxia, glycolysis and HIF-1 signalling pathways. Mechanistically, we found that USP25 directly interacts with HIF-1 and that its deubiquitylase activity regulates HIF-1 protein stability, nuclear translocation and transcriptional activity. Moreover, treatment with a novel USP25 inhibitor resulted in a dramatic loss of murine and patient-derived organoid viability, HIF-1 signalling, and consequently induced substantial regression of murine and human organoid-derived xenografts in vivo. Thus, USP25 is a promising therapeutic target for the treatment of human PDAC.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human) Mus Musculus (mouse)

TISSUE(S): Pancreatic Acinar Cell, Pancreas

DISEASE(S): Pancreatic Carcinoma

SUBMITTER: Steven Howell  

LAB HEAD: James McCrae

PROVIDER: PXD023424 | Pride | 2022-05-19

REPOSITORIES: Pride

altmetric image

Publications


Deubiquitylating enzymes (DUBs) play an essential role in targeted protein degradation and represent an emerging therapeutic paradigm in cancer. However, their therapeutic potential in pancreatic ductal adenocarcinoma (PDAC) has not been explored. Here, we develop a DUB discovery pipeline, combining activity-based proteomics with a loss-of-function genetic screen in patient-derived PDAC organoids and murine genetic models. This approach identifies USP25 as a master regulator of PDAC growth and m  ...[more]

Similar Datasets

2020-09-18 | PXD021557 | Pride
2020-06-16 | GSE142467 | GEO
2013-04-04 | E-GEOD-45771 | biostudies-arrayexpress
2022-03-01 | GSE166077 | GEO
2016-07-06 | E-GEOD-84008 | biostudies-arrayexpress
2022-07-05 | PXD028802 | Pride
2024-01-03 | PXD035417 | Pride
2016-01-18 | E-GEOD-50471 | biostudies-arrayexpress
2022-12-23 | PXD039096 | iProX
2008-07-11 | E-GEOD-11660 | biostudies-arrayexpress